Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2011 Jan 15

PMID 21234295

Citations 17

Authors

Julien Hadoux

Stephane Vignot

Thibault de La Motte Rouge

Affiliations

Soon will be listed here.

Abstract

Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful monitoring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and future perspectives.

Citing Articles

circFOXO3 Induced by KLF16 Modulates Clear Cell Renal Cell Carcinoma Growth and Natural Killer Cell Cytotoxic Activity through Sponging miR-29a-3p and miR-122-5p.

Yang F, Chen Y, Luo L, Nong S, Li T Dis Markers. 2022; 2022:6062236.

PMID: 36072902 PMC: 9444423. DOI: 10.1155/2022/6062236.

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew ().

Belkacemi L, Sun Y, Darmani N Front Pharmacol. 2022; 13:848673.

PMID: 35444553 PMC: 9014009. DOI: 10.3389/fphar.2022.848673.

LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma.

Guo R, Zou B, Liang Y, Bian J, Xu J, Zhou Q Cell Death Dis. 2021; 12(7):689.

PMID: 34244473 PMC: 8270952. DOI: 10.1038/s41419-021-03955-7.

Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo.

Takai T, Tsujino T, Yoshikawa Y, Inamoto T, Sugito N, Kuranaga Y Mol Ther. 2019; 27(5):1017-1027.

PMID: 30930112 PMC: 6520334. DOI: 10.1016/j.ymthe.2019.03.004.

miR-216a-5p acts as an oncogene in renal cell carcinoma.

Chen P, Quan J, Jin L, Lin C, Xu W, Xu J Exp Ther Med. 2018; 15(4):4039-4046.

PMID: 29556270 PMC: 5844176. DOI: 10.3892/etm.2018.5881.

References

Morelon E, Stern M, Israel-Biet D, Correas J, Danel C, Mamzer-Bruneel M . Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001; 72(5):787-90. DOI: 10.1097/00007890-200109150-00008. View

Lunardi G, Armirotti A, Nicodemo M, Cavallini L, Damonte G, Vannozzi M . Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clin Ther. 2009; 31(8):1812-9. DOI: 10.1016/j.clinthera.2009.08.018. View

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605):2103-11. DOI: 10.1016/S0140-6736(07)61904-7. View

Vignot S, Faivre S, Aguirre D, Raymond E . mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005; 16(4):525-37. DOI: 10.1093/annonc/mdi113. View

Punt C, Boni J, Bruntsch U, Peters M, Thielert C . Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol. 2003; 14(6):931-7. DOI: 10.1093/annonc/mdg248. View

Muss H, COSTANZI J, Leavitt R, Williams R, Kempf R, Pollard R . Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987; 5(2):286-91. DOI: 10.1200/JCO.1987.5.2.286. View

Patel P, Senico P, Curiel R, Motzer R . Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009; 7(1):24-7. PMC: 3740755. DOI: 10.3816/CGC.2009.n.004. View

Park I, Bachmann R, Shirazi H, Chen J . Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem. 2002; 277(35):31423-9. DOI: 10.1074/jbc.M204080200. View

Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J . Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004; 22(12):2336-47. DOI: 10.1200/JCO.2004.08.116. View

10.

Faivre S, Kroemer G, Raymond E . Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5(8):671-88. DOI: 10.1038/nrd2062. View

11.

Duran I, Siu L, Oza A, Chung T, Sturgeon J, Townsley C . Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006; 42(12):1875-80. DOI: 10.1016/j.ejca.2006.03.015. View

12.

Atkins M, Sparano J, Fisher R, Weiss G, Margolin K, Fink K . Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11(4):661-70. DOI: 10.1200/JCO.1993.11.4.661. View

13.

Motzer R, Bacik J, Mazumdar M . Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res. 2004; 10(18 Pt 2):6302S-3S. DOI: 10.1158/1078-0432.CCR-040031. View

14.

Boni J, Hug B, Leister C, Sonnichsen D . Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol. 2009; 36 Suppl 3:S18-25. DOI: 10.1053/j.seminoncol.2009.10.009. View

15.

Peralba J, deGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G . Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res. 2003; 9(8):2887-92. View

16.

Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S . mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets. 2008; 8(8):647-65. DOI: 10.2174/156800908786733513. View

17.

Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S . Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28(13):2144-50. DOI: 10.1200/JCO.2009.26.7849. View

18.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

19.

Motzer R, Hudes G, Curti B, Mcdermott D, Escudier B, Negrier S . Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007; 25(25):3958-64. DOI: 10.1200/JCO.2006.10.5916. View

20.

Hudes G, Berkenblit A, Feingold J, Atkins M, Rini B, Dutcher J . Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009; 36 Suppl 3:S26-36. DOI: 10.1053/j.seminoncol.2009.10.013. View